HONG KONG (Nikkei Markets) -- Shanghai Henlius Biotech expects to raise up to HK$3.74 billion ($477 million) from an initial public offering in Hong Kong, according to sources.
The Chinese biopharmaceutical company, being spun off from Hong Kong-and-Shanghai-listed Shanghai Fosun Pharmaceutical Group, is offering 64.7 million shares in an indicative pricing range of HK$49.60 to HK$57.80 apiece, according to two persons familiar with the matter.
